MENU
RAPP
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Rapport Therapeutics (RAPP) Ownership - Who owns Rapport Therapeutics?
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
531.04M
P/E Ratio
12.13
Total Cash
285.38M
Projected Growth
N/A
Total Debt
7.84M
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
7.82
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
RAPP
Capitalization
531M
P/E Ratio
12.13
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
285M
Total Cash/Share
7.82
Total Debt
7.84M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
286M
P/B Ratio
2.02
Cash Flow
N/A
Earnings
-3.82
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
37K
Current Ratio
31.01
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-92.14M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-31.36
Shares Held By Institutions
501M
Shares Outstanding - Current
36.5M
Total Liabilities
16.2M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-17.982
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information